Tachmed, expert developers of intuitive at-home digital diagnostic technology, has today announced the appointment of Mark Kessler as COO, following completion of its recent seed round of investments.
Kessler, who has extensive C-suite level and operational experience, having managed businesses and teams across the Americas, EMEA and Asia, will work closely with Tachmed co-founder and chief executive officer, Paul Christie, to execute the businesses’ ambitious international growth strategy.
Established in 2018, Tachmed develops intuitive and easy-to-use smart health meters, designed to capture biomarkers of diseases, that disseminates reporting directly through to the clinician and/or other interested parties.
As well as dramatically improving the rates and accuracy of diagnosis, the data collected systematically and in real time can transform how the industry approaches future healthcare threats and improve global health security.
Before joining Tachmed, Kessler held a number of senior positions within global asset management firms and investment banks, including Alphadyne Asset Management, Woodbine Capital Advisors, Suranya Capital Partners, and JPMorgan. During this time, Kessler was responsible for global strategy, operational management, risk analysis, compliance, marketing, and finance.
Commenting on his new role, Mark Kessler said:
“I’m thrilled to be joining Tachmed at such an exciting time. Their digital diagnostics system, due to launch in 2023, will seriously disrupt the market and finally allow healthcare providers to deliver a better, fairer and faster service to patients.
“I am incredibly impressed by the knowledge and expertise of all those working on the platform, and very much look forward to making a positive impact on the business.”
Commenting on Mark’s appointment and further expansion of the Tachmed senior leadership team, Paul said:
“It’s brilliant to have Mark onboard. I know that he will play a vital role in helping us to achieve our aim of bringing safe, easy and affordable digital diagnostic devices to the masses.
“Our targets for 2023 are certainly ambitious, but I’m certain that we have the right people onboard to ensure we achieve them.”
Lord Beaverbrook, co-founder and executive chairman at Tachmed said:
“Mark is joining the business at a truly exciting time. With the Tachmed digital diagnostics system due to launch later this year, the addition of an experienced COO will undoubtedly help us to achieve our international growth objectives, as well as engaging with new partners and prospective customers.”
With submissions pending for regulatory authorisation by the UK MHRA, EU CE notification bodies and US FDA, Tachmed continues to develop an impressive array of global stakeholder partnerships with leading universities, tech companies and supra-national organisations.
For more information visit: https://tachmed.com/